April 2004

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-04-02-2004
Volume 28
Issue 4

pharmaceutical science and technology news

External Link - article-91089.pdf

Articles in this issue
Spotlight on Business Risk
Vibration Technology for Active Dry-Powder Inhalers
In the Spotlight April 2004
FDA Attacks Counterfeits
Synthetic Excipients Challenge All-Natural Organics
April 2004
Controlled-Release Dosage Forms for Diltiazem Hydrochloride
Recent Videos
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content
Darmstadt, Germany - November 10, 2021: A building at the headquarters of science and technology company Merck KGaA. | Image Credit: © Anne Czichos - stock.adobe.com

MilliporeSigma and Simtra Launch Five-Year Agreement for Drug Substance, Drug Manufacturing Services

Patrick Lavery
June 11th 2025
Article

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Logo of Merck KgA, Merck is a German multinational science and technology company. | Image Credit: © Robert - stock.adobe.com

China’s NMPA Approves Merck KGaA Treatment for Tenosynovial Giant Cell Tumor

Patrick Lavery
June 10th 2025
Article

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Orlando, Florida, USA - February 8, 2020: Hesperos headquarters in Orlando, Florida, USA. Hesperos is a biotechnology company that develops human-on-a-chip systems. | Image Credit: © JHVEPhoto - stock.adobe.com

Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia

Patrick Lavery
June 9th 2025
Article

The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.

cold storage room with shelves stocked with boxes and containers. Cooling fans and a digital temperature control panel ensure precise climate conditions. refrigeration - storage shelves | Image Credit: © Grispb - stock.adobe.com

Tjoapack Announces Packaging, Cold Chain Expansions in US and Netherlands

Patrick Lavery
June 9th 2025
Article

Most of the company’s new additions, if not already online, will be scheduled for commissioning, validation, or qualification before the fourth quarter of 2025.